Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences

Basit Öğe Kaydı
dc.authorid0000-0003-2440-7529
dc.authorid0000-0001-6019-0430
dc.authorscopusid56035868800
dc.authorscopusid7004204730
dc.authorscopusid57203430154
dc.authorscopusid6603745569
dc.authorscopusid57202004238
dc.authorscopusid55750439300
dc.authorscopusid6602163658
dc.authorwosidKARAALİ, Rıdvan/AAQ-1018-2020
dc.authorwosidYILDIZ, ORHAN/B-2193-2018
dc.contributor.authorÖrmeci, Necati
dc.contributor.authorSezgin, Orhan
dc.contributor.authorKaraali, Rıdvan
dc.contributor.authorAygen, Bilgehan
dc.contributor.authorTuran, Dilara
dc.contributor.authorYaras, Serkan
dc.contributor.authorAsiller, Özgün
dc.contributor.authorKaraali, Rıdvan
dc.contributor.authorErdem, İlknur
dc.date.accessioned2022-05-11T14:37:23Z
dc.date.available2022-05-11T14:37:23Z
dc.date.issued2019
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları Ana Bilim Dalı
dc.description.abstractIntroduction Both hepatitis C virus infection (HCV) and chronic kidney disease (CKD) have been comorbid illnesses with increasing morbidity and mortality. The present study was conducted to present real-life experiences about treatment of HCV and CKD with a fixed-dose combination of paritaprevir 150 mg/day, ritonavir 100 mg/day as a booster, ombitasvir 25 mg/day, and dasabuvir 250 mg twice/day, the PROD regimen. Patients and methods This was a multicenter, retrospective cohort study. Seventy-five patients with both HCV and CKD were treated with a PROD-based regimen with or without ribavirin. Fifty-three of 75 patients were on maintenance hemodialysis program. Seven patients had compensated liver cirrhosis. The patients with genotype 1a or compensated liver cirrhosis were treated with the PROD regimen and ribavirin in a dose of 200 mg every other day for 12 weeks. The patients with genotype 1b were treated with PROD for 12 weeks. The patients with genotype 4 were treated with a combination of paritaprevir, ritonavir, ombitasvir, and ribavirin 200 mg every other day. Results All patients except one were HCV-RNA negative (98.6%) at the end of treatment. One patient had decompensated after the fourth day of therapy. She stopped the treatment, and she was exitus after 2 months. Two patients died of reasons not related to the drugs 2 months after negativity of HCV-RNA. Sustained viral rate 12 weeks after treatment was found in 96% of the patients. Conclusion The PROD regimen was very effective and safe for treatment in patients with HCV and CKD who were in stages 4 and 5. Copyright (C) 2019 Wolters Kluwer Health, Inc. All rights reserved.
dc.identifier.doi10.1097/MEG.0000000000001334
dc.identifier.endpage539
dc.identifier.issn0954-691X
dc.identifier.issn1473-5687
dc.identifier.issue4en_US
dc.identifier.pmid30672829
dc.identifier.scopus2-s2.0-85062408065
dc.identifier.scopusqualityQ2
dc.identifier.startpage534
dc.identifier.urihttps://doi.org/10.1097/MEG.0000000000001334
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8675
dc.identifier.volume31
dc.identifier.wosWOS:000480690600018
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKaraali, Rıdvan
dc.institutionauthorErdem, İlknur
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofEuropean Journal of Gastroenterology & Hepatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjecthepatitis C virus
dc.subjectkidney diseases
dc.subjectPROD regimen
dc.subjecttreatment
dc.subjectExtrahepatic Manifestations
dc.subjectTransplant Recipients
dc.subjectHemodialysis-Patients
dc.subjectActing Antivirals
dc.subjectDialysis Patients
dc.subjectHcv Infection
dc.subjectGenotypes 1
dc.subjectEfficacy
dc.subjectOmbitasvir/Paritaprevir/Ritonavir
dc.subjectSafety
dc.titleEffectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
8675.pdf
Boyut:
180.56 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu